IO Biotech Announces Participation in Upcoming Investor Conferences
November 08 2023 - 4:30PM
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical
company developing novel, immune-modulating cancer vaccines based
on its T-win® technology platform, today announced its
participation in the upcoming investor conferences:
Event: Jefferies London Healthcare
ConferenceLocation: LondonOne-on-one meetings: Wednesday, November
15, 2023Participants: Mai-Britt Zocca, PhD, President and CEO and
Amy Sullivan, CFO
Event: Piper Sandler 35th Healthcare
ConferenceLocation: New York, New YorkFireside chat: Wednesday,
November 29, 2023 at 4:30 pm ETPresenter: Mai-Britt Zocca, PhD,
President & CEOWebcast link:
https://event.webcasts.com/starthere.jsp?ei=1643140&tp_key=1d3631cba2
A webcast replay of the presentations will be
available on IO Biotech’s website at www.iobiotech.com for 90 days
following the presentation.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical
company developing novel, immune-modulating therapeutic cancer
vaccines based on its T-win® vaccine platform. The T-win platform
is a novel approach to cancer vaccines designed to activate T cells
to target tumor cells and immunosuppressive cells in the tumor
microenvironment. IO Biotech is advancing its lead cancer vaccine
candidate, IO102-IO103, in clinical trials, and additional pipeline
candidates through preclinical development. Based on positive Phase
1/2 first line advanced melanoma data, IO102-IO103, in combination
with pembrolizumab, has been granted a breakthrough therapy
designation for the treatment of unresectable/metastatic melanoma
by the US Food and Drug Administration. IO Biotech is headquartered
in Copenhagen, Denmark and has US headquarters in New York, New
York.
About IO102-IO103
IO102-IO103 is an investigational
immune-modulating therapeutic cancer vaccine designed to target the
immunosuppressive mechanisms mediated by the proteins indoleamine
2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1). The
company is currently conducting a pivotal Phase 3 trial
(IOB-013/KN-D18; NCT05155254) evaluating IO102-IO103 in combination
with pembrolizumab in first-line advanced melanoma patients, a
Phase 2 basket trial (IOB-022/KN-D38; NCT05077709) evaluating
IO102-IO103 in combination with pembrolizumab in first-line
advanced non-small cell lung cancer and head and neck cancer
(SCCHN), and a Phase 2 basket trial (IOB-032/PN-E40; NCT05280314)
evaluating IO102-IO103 plus pembrolizumab as a perioperative
treatment in solid tumors including melanoma and SCCHN.
The clinical trials are sponsored by IO Biotech
and conducted in collaboration with Merck and Merck is supplying
pembrolizumab. IO Biotech maintains global commercial rights to
IO102-IO103.
KEYTRUDA® is a registered trademark of Merck
Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,
Rahway, NJ, USA.
For further information, please visit
www.iobiotech.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements, including
regarding the timing of the interim analysis of our Phase 3 trial,
current or future clinical trials, their progress, enrollment or
results, or the company’s financial position or cash runway, are
based on IO Biotech’s current assumptions and expectations of
future events and trends, which affect or may affect its business,
strategy, operations or financial performance, and actual results
and other events may differ materially from those expressed or
implied in such statements due to numerous risks and uncertainties.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Because forward-looking statements are inherently subject to risks
and uncertainties, you should not rely on these forward-looking
statements as predictions of future events. These forward-looking
statements speak only as of the date hereof and should not be
unduly relied upon. Except to the extent required by law, IO
Biotech undertakes no obligation to update these statements,
whether as a result of any new information, future developments or
otherwise.
Contact:Maryann Cimino,
Director of Investor Relations IO Biotech,
Inc.617-710-7305mci@iobiotech.com
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
From Apr 2024 to May 2024
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
From May 2023 to May 2024